文献速递脑血管病

替罗非班治疗分支动脉粥样硬化病相关卒中:STRATEGY随机临床试验

Tirofiban for Branch Atheromatous Disease-Related Stroke: The STRATEGY Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2026-01-01

STRATEGY试验在中国38家医院纳入970例48小时内经MRI确诊的分支动脉粥样硬化病相关急性缺血性卒中患者,随机接受替罗非班或安慰剂联合阿司匹林治疗。

要点

  • 替罗非班联合阿司匹林未显著降低BAD相关卒中患者END或新发卒中风险。
  • 替罗非班组中重度出血发生率为0.2%,与安慰剂组无显著差异。

核心结论

  • 在BAD相关卒中患者中,静脉替罗非班联合阿司匹林与单用阿司匹林相比未显著降低END或卒中风险,也未增加中重度出血风险。

研究设计与样本

  • 多中心、双盲、随机、安慰剂对照试验(STRATEGY),在中国38家医院进行。
  • 纳入970例48小时内经MRI确诊的BAD相关急性缺血性卒中患者,随机分为替罗非班组(486例)和安慰剂组(484例)。
  • 替罗非班用法:0.4 µg/kg/min持续30分钟,随后0.1 µg/kg/min持续24小时;所有患者随机当日接受阿司匹林300 mg负荷量,后100 mg/日至90天。

主要发现

  • 患者中位年龄63.0岁(IQR 56.0-70.0),男性607例(62.6%),女性363例(37.4%)。

临床怎么用

  • 对于BAD相关急性缺血性卒中患者,静脉替罗非班联合阿司匹林未能显著改善早期神经功能恶化或新发卒中风险,不推荐常规用于该人群的二级预防。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with branch atheromatous disease (BAD)-related stroke are predisposed to early neurological deterioration (END) and disability. However, large-scale clinical trials focused on the prevention of the deterioration and recurrent stroke in this population are currently lacking. OBJECTIVE: To evaluate the efficacy and safety of intensive antiplatelet therapy combining the tirofiban with aspirin for patients with BAD-related stroke. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was the multicenter, double-blind, randomized, placebo-controlled STRATEGY trial, conducted across 38 hospitals in China. Participants were patients with BAD-related acute ischemic stroke confirmed by magnetic resonance imaging within 48 hours of symptom onset were eligible for enrollment. Enrollment occurred from November 15, 2022, to November 19, 2024, with a 90-day follow-up period for all participants. Investigators, patients, and outcome assessors were blinded to treatment assignment. INTERVENTIONS: Eligible participants were randomized to receive either intravenous tirofiban or placebo (0.4 µg/kg/min for 30 minutes followed by 0.1 µg/kg/min for 24 hours). All patients received a 300-mg loading dose of aspirin on the day of randomization, followed by 100 mg daily until day 90. MAIN OUTCOMES AND MEASURES: The primary efficacy end point was END within 7 days or new stroke within 90 days. The primary safety end point was moderate or severe bleeding. RESULTS: Of 1378 patients with acute ischemic stroke screened for eligibility, 408 were excluded for ineligible imaging findings, other exclusion criteria, lack of consent, or additional reasons, leaving 970 participants who underwent randomization (486 assigned to tirofiban plus aspirin, 484 to placebo plus aspirin). The median (IQR) age was 63.0 (56.0-70.0) years; 607 patients (62.6%) were male and 363 (37.4%) female. The incidence of the primary efficacy end point was 79 patients (17.1%) in the tirofiban group and 89 (19.6%) in the placebo group (hazard ratio, 0.88; 95% CI, 0.65-1.19; P = .39). The incidence of the primary safety end point was 1 of 486 patients (0.2%) in the tirofiban group and 0 patients in the placebo group (P > .99). CONCLUSIONS AND RELEVANCE: This study found that in patients with BAD-related stroke, intravenous tirofiban combined with aspirin did not significantly reduce the risk of END or stroke compared with aspirin alone, nor was it associated with an increased risk of moderate or severe bleeding. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05310968.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Wang Y, Liao X, Feng S, et al. Tirofiban for Branch Atheromatous Disease-Related Stroke: The STRATEGY Randomized Clinical Trial. JAMA Neurol. 2026. PMID: 42671865. doi:10.1001/jamaneurol.2026.2855

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。